AI summary · may contain errors
Access to cancer genomics and precision oncology is profoundly unequal across and within countries, leaving millions of patients without guideline-indicated interventions each year.
- 1 cited this week
Elsevier BV · Oncology · ISSN 1470-2045, 1474-5488
Rebuilt
AI summary · may contain errors
Access to cancer genomics and precision oncology is profoundly unequal across and within countries, leaving millions of patients without guideline-indicated interventions each year.
AI summary · may contain errors
Infections are linked to 2.3 million new cancer cases globally in 2024, representing 12% of all new cancer diagnoses worldwide.
Newest first · last 60 days
AI summary · may contain errors
Whole-genome sequencing across 17,029 solid tumours identified immediately actionable alterations in 18.9% of UK primary cancers and 25.9% of Netherlands metastatic cancers.
AI summary · may contain errors
Risovalisib achieved an objective response rate of 35% (95% CI 25–46) in 84 patients with recurrent or persistent PIK3CA-mutated ovarian clear cell carcinoma.
AI summary · may contain errors
First-line pumitamig plus nab-paclitaxel in advanced or metastatic triple-negative breast cancer achieved a confirmed objective response rate of 73·8% (31/42).
AI summary · may contain errors
Five-year net survival for eleven common cancers in the Commonwealth is estimated at 30·7% in 2020, ranging from 4·1% in low-income countries to 59·0% in high-income countries.
AI summary · may contain errors
In 1049 patients with renal cell carcinoma and brain metastases treated from 2016–2022, median overall survival was 20·0 months and varied widely by updated Renal GPA.
AI summary · may contain errors
Estimated 10-year direct treatment costs for newly diagnosed cancers in 2022 total $771·48 billion (95% UI 719·99–823·81), driven most by breast cancer at $96·07 billion.
AI summary · may contain errors
Reporting in randomized adjuvant systemic therapy trials should quantify the proportion of treated patients with prespecified HRQOL deterioration and its duration, using validated scales.
AI summary · may contain errors
Digital breast tomosynthesis plus synthesised 2D mammography yields a lower invasive interval cancer rate than digital mammography in 24-month screen-negative follow-up (14·2 vs 18·6 per 10,000).
AI summary · may contain errors
Nationally reported recurrent spending on cancer control is available for only 81 of 218 countries and territories, with a mean per-capita level of $88·9 (SD 145·3).
AI summary · may contain errors
PRISM assessed 50 national cancer control plans and found median overall comprehensiveness of 2·78 (IQR 2·25–3·09), with financing, outcomes, and threats consistently lowest.
Journals this month
Topics moving, week to 18 Nov 2026
By field